enoxaparin sodium ledraxen süstelahus süstlis
venipharm - naatriumenoksapariin - süstelahus süstlis - 10000rÜ 1ml 30tk; 10000rÜ 1ml 24tk; 10000rÜ 1ml 2tk; 10000rÜ 1ml 12tk; 10000rÜ 1ml 10tk
enoxaparin sodium ledraxen süstelahus süstlis
venipharm - naatriumenoksapariin - süstelahus süstlis - 4000rÜ 0.4ml 10tk; 4000rÜ 0.4ml 20tk; 4000rÜ 0.4ml 1tk; 4000rÜ 0.4ml 50tk; 4000rÜ 0.4ml 6tk; 4000rÜ 0.4ml 30tk; 4000rÜ 0.4ml 2tk
enoxaparin sodium ledraxen süstelahus süstlis
venipharm - naatriumenoksapariin - süstelahus süstlis - 6000rÜ 0.6ml 24tk; 6000rÜ 0.6ml 2tk; 6000rÜ 0.6ml 30tk; 6000rÜ 0.6ml 20tk; 6000rÜ 0.6ml 6tk; 6000rÜ 0.6ml 12tk
enoxaparin sodium ledraxen süstelahus süstlis
venipharm - naatriumenoksapariin - süstelahus süstlis - 8000rÜ 0.8ml 2tk; 8000rÜ 0.8ml 12tk; 8000rÜ 0.8ml 10tk; 8000rÜ 0.8ml 1tk; 8000rÜ 0.8ml 24tk; 8000rÜ 0.8ml 30tk; 8000rÜ 0.8ml 50tk; 8000rÜ 0.8ml 6tk
enoxaparin sodium ledraxen süstelahus süstlis
venipharm - naatriumenoksapariin - süstelahus süstlis - 2000rÜ 0.2ml 20tk; 2000rÜ 0.2ml 6tk; 2000rÜ 0.2ml 1tk; 2000rÜ 0.2ml 10tk; 2000rÜ 0.2ml 50tk; 2000rÜ 0.2ml 2tk
pemetrexed pfizer (previously pemetrexed hospira)
pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastilised ained - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastilised ained - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.
foscarnet sodium tillomed infusioonilahus
tillomed pharma gmbh - naatriumfoskarnet - infusioonilahus - 24mg 1ml 250ml 1tk; 24mg 1ml 250ml 10tk
vantavo (previously alendronate sodium and colecalciferol, msd)
n.v. organon - alendronic acid, colecalciferol - osteoporoos, postmenopausis - narkootikumid luuhaiguste raviks - menopausijärgse osteoporoosi ravi d-vitamiini puudulikkusega patsientidel. vantavo vähendab lülisamba ja puusaluu murrud. ravi postmenopausis osteoporoosi patsientidel, kes ei saanud vitamiin-d täiendamine ja on risk vitamiin-d puudulikkus. vantavo vähendab lülisamba ja puusaluu murrud.
triumeq
viiv healthcare b.v. - dolutegravir sodium, lamivudine, abacavir (as sulfate) - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents in triumeq.